CAS: 93319-65-4; Pyridazin-3-Ylmethanamine

该化合物是一种有机化合物,其特征为:有六人组成的芳香环环,含有两个氮原子;该化合物的特征是附于的甲基胺组,有助于其基本性和潜在反应性;通常,3-丙烯基甲基胺的化合物具有极地溶剂溶解性等特性,因为有可溶解氢的铁矿功能组存在,这种物质可以进行氢结合;存在基胺会引发特定的生物活动,使其对医药化学和药物开发感兴趣;此外,由于该矿群的核循环性质,该化合物可能参与各种化学反应,包括通灵和细胞反应,其化学编号为93319-65-4,从而能够准确识别化学数据库和文献中的溶解特性;总体而言,三-丙基氮甲基胺是其潜在药物应用及其独特结构特征的一种化合物.

结构式图片

相似化合物

1337879-71-6 1228788-25-7 2375272-95-8

物理性质

MSDS等安全信息

欧盟法规

C&L通报

上下游产品

pyridazine-3-carbonitrile 3-methylpyridazine pyridazine-3-carbaldehyde oxime (Z)-2-{1-[2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(pyridazin-3-ylmethyl)acetamide 7-[2-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)ethyl]imidazo[1,5-b]pyridazine

合成工艺路线路线简述

  • 52348-44-4 = 93319-65-4
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Ethanol; 1 H,Rt
    标题:Synthesis And Structure-Activity Relationships Of Amide Derivatives Of (4,4-Difluoro-1,2,3,4-Tetrahydro-5H-1-Benzazepin-5-Ylidene)Acetic Acid As Selective Arginine Vasopressin V2 Receptor Agonists
    作者:Tsukamoto,Issei; Koshio,Hiroyuki; Kuramochi,Takahiro; Saitoh,Chikashi; Yanai-Inamura,Hiroko; Et Al
    参考文献:Bioorganic & Medicinal Chemistry 日期:2009 卷标:17(8) 页码:3130-3141]

    53896-49-4 = 93319-65-4
    反应条件:1.1 Reagents: Hydrogen,Ammonia Catalysts: Nickel Solvents: Methanol; 60 Psi,40 °C
    标题:Preparation Of Arylsulfonyl-Substituted Indoles As Cb1 Receptor Modulators
    参考文献:World Intellectual Property Organization]

    = 93319-65-4 [标题:Reaction Conditions
    标题:(Pyridylaminoalkylamino)Thiadiazoles As Histamine H1 Antagonists
    参考文献:European Patent Organization]

    1279818-63-1 = 93319-65-4
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Ethanol; Overnight,Rt
    标题:Preparation Of Purinamine Compounds Treatment Of Neurodegenerative And Mitochondrial Disease
    参考文献:World Intellectual Property Organization]

    1072806-50-8 = 93319-65-4
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Water; 1 H,Reflux; Reflux -> Rt
    标题:Heterocyclic Compounds As Stearoyl-Coa Desaturase Inhibitors And Their Preparation,Pharmaceutical Compositions And Use In The Treatment Of Diseases
    参考文献:World Intellectual Property Organization]

    = 93319-65-4 [标题:Reaction Conditions
    标题:Preparation Of Indoylmethanamine Derivatives And Analogs For Use As Lysyl Oxidase-Like 2 Inhibitors
    参考文献:World Intellectual Property Organization
📜3-甲基哒嗪 以 甲醇,Palladium On Charcoal 作为反应溶剂,以99%的收率获得产物3-哒嗪甲胺
参考文献:Histamine Antagonist Triadiazole Derivatives,Compositions,And Method
标题:Histamine Antagonist Triadiazole Derivatives,Compositions,And Method
摘要:新的3,4-二氨基-1,2,5-噻二唑氧化物衍生物,是组织胺h.Sub.1-拮抗剂.该发明的一种特定化合物是3-[3-[n-(4-氟苄基)-N-吡啶-2-基氨基]丙基氨基]-4-[嘧啶-4-基甲氨基]-1,2,5-噻二唑-1-氧化物.

专利信息


专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:DE-102011106849-A1
优先权日:2010-12-15
标 题:Process for the synthesis of N-N linked and around the N-N bond of rotation-inhibited bis-N-heterocyclic carbenes and their use as ligands for metal complexes

专利号:US-10308615-B2
优先权日:2015-05-29
标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme
发明人：CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献

参考DOI号:10.1016/j.bmc.2009.03.001
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知